September 6, 2017 / 6:41 AM / 19 days ago

Drugmaker Vectura's H1 revenue up 6 pct on rising sales of inhaled products

Sept 6 - Vectura said revenue rose 6 percent in the first half of the year, driven by rising sales of its recently launched inhaled products and the continued weakness of sterling against a basket of its main trading currencies.

The FTSE-250 firm that specializes in developing lung drugs said revenue rose to 78.8 million pounds ($102.67 million) in the six months ended June 30 from 73.9 million pounds in the prior-year period.

The company posted a higher loss before tax of 44.5 million pounds, up from a loss of 22.4 million pounds earlier, as amortisation expenses continued to increase following its merger with SkyePharma in June.

$1 = 0.7675 pounds Reporting by Justin George Varghese in Bengaluru, editing by Louise Heavens

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below